Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 4991-4994, October 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Higasa, M.
Right arrow Articles by Dohi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Higasa, M.
Right arrow Articles by Dohi, Y.

In Vivo Generation of Tumor-specific Cytotoxic T-Cells in the Regional Lymph Node: Effect of Subcutaneous Inoculation of mls-disparate Spleen Cells around Implanted Tumors in Mice1

Minoru Higasa, Kazuhiko Yamada, Yutaka Takagaki, Masahiro Aoki, Sohei Shinka and Yoshitane Dohi2

Department of Bacteriology, Osaka University Medical School, Osaka 565, and Department of Medical Zoology, Hyogo College of Medicine, Nishinomiya, Japan

Generation of immunological resistance to a B-cell tumor was attempted by inoculating histoincompatible spleen cells around the sites of implanted tumor cells. Syngeneic hybridomas developed in the regional area of 96% of the control mice but in 4% of the mice that had received s.c. inoculation of H-2-matched, mls-disparate spleen cells. The regional lymph node cells of the mice in which tumors did not develop showed direct cytotoxicity against the hybridoma cells. This cytotoxicity was sensitive to treatment with the monoclonal anti-Thy-1.2 and complement and was specific for the tumor cells. After s.c. inoculation of mls-disparate spleen cells, cells of the regional lymph node were shown to produce interleukin 2. Primary cultures of the recipient lymph node cells and the donor spleen cells in the presence of T-cell growth factors showed that the tumor-specific cytotoxic T-lymphocytes were derived from the donor spleen cells. These results strongly suggest that on injection of mls antigen-disparate spleen cells, injected splenic T-cells specific for the tumor developed into functional cytotoxic T-lymphocytes with the help of interleukin 2 which was produced by the mixed lymphocyte reaction in vivo and thus prevented tumor growth. The possibility of clinical application of this procedure in the immunotherapy of neoplasms is discussed.

1 Supported by Grants-in-Aid for Scientific Research from the Japanese Government.

2 To whom requests for reprints should be addressed, at the Department of Bacteriology, Osaka University Medical School, Yamadaoka 3-1, Suita, Osaka 565, Japan.

Received 4/ 9/86. Revised 7/ 1/86. Accepted 7/ 3/86.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.